Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for BAT2506 in ...

Results The IP-MS analysis, followed by validation in patients with SSc, revealed a significant elevation in anti-PRMT5 antibodies among patients with SSc. These antibodies exhibited robust diagnostic ...

In general, anti-TNF therapy should not be initiated in the presence of severe infections and should be interrupted when these occur during treatment; however, they can be reintroduced once ...

Methods Mice lacking TNF expression by distinct cell types, such as myeloid cells and T or B lymphocytes, were subjected to collagen-induced arthritis (CIA) and collagen antibody-induced ... types may ...

Monitoring individuals with robust and clinically validated tests for both drugs and antidrug antibodies is the only way to ensure cost-effective, long-term use of anti-TNF-α biopharmaceuticals.

This Phase 1 study evaluated the safety and efficacy of botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody ... intervention using steroids and TNF-alpha inhibitors. No Grade 4 or 5 TRAEs ...

Those who used anti-TNF and anti-IL-17 drugs had a lower incidence and risk for Parkinson’s vs. those who did not. Patients treated with anti-IL-17 only had a lower risk for PD compared with ...